First Page | Meta Content | |
---|---|---|
![]() | Document Date: 2014-11-06 23:49:41Open Document File Size: 681,38 KBShare Result on FacebookCompanyBOTOX / MSAC / Australian Refined Diagnosis Related Group / Allergan Australia Pty Ltd / PBS / /CurrencyUSD / /EventProduct Issues / FDA Phase / Product Recall / /IndustryTermbotulinum toxin products / health services / agreed clinical protocols / clinical management / botulinum toxin product / conservative management / health technology assessments / /MarketIndexMBS / /MedicalConditionrefractory migraine / urinary incontinence / adult spina bifida / neurologic disorder / multiple sclerosis / defined neurological illness / urinary tract infections / idiopathic overactive bladder / spinal cord injury / /MedicalTreatmentclinical protocols / /OrganizationPharmaceutical Benefits Advisory Committee / Therapeutic Goods Administration / Australian Health Ministers’ Advisory Council / Medical Services Advisory Committee / Medicare / /PersonBOTULINUM TOXIN / /Positionanaesthetist / Governor / Minister / Executive / General / /ProductBOTULINUM TOXIN INJECTIONS / effects necessitating / Intravesical injection / intravesical / management / /Technologyagreed clinical protocols / /URLwww.msac.gov.au / /SocialTag |